OVX033 / Osivax - LARVOL DELTA

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Osivax | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

OVX033, N-based T-cell broad-spectrum vaccine candidate against all sarbecovirus is safe and immunogenic in non-human primates (ISIRV-OPTIONS XII 2024) - No abstract available

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Osivax | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Osivax | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Osivax

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease